Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARCTNASDAQ:HRTXNASDAQ:RVNCNASDAQ:STOK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARCTArcturus Therapeutics$9.11-3.9%$14.89$8.70▼$45.00$247.06M3.41459,322 shs579,462 shsHRTXHeron Therapeutics$2.10-1.9%$2.05$1.04▼$3.93$319.89M1.392.37 million shs1.11 million shsRVNCRevance Therapeutics$3.65$3.65$2.30▼$6.65$381.02M0.93.14 million shsN/ASTOKStoke Therapeutics$5.94-5.7%$8.94$5.66▼$17.58$321.22M1.09719,672 shs1.15 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARCTArcturus Therapeutics0.00%-21.33%-37.39%-52.23%-71.50%HRTXHeron Therapeutics0.00%-7.08%-12.13%+17.32%-23.64%RVNCRevance Therapeutics0.00%0.00%0.00%+5.19%-17.23%STOKStoke Therapeutics0.00%-17.61%-25.84%-46.10%-52.74%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARCTArcturus Therapeutics2.9334 of 5 stars4.60.00.00.02.22.51.3HRTXHeron Therapeutics2.8354 of 5 stars3.50.00.04.20.01.70.6RVNCRevance Therapeutics1.9386 of 5 stars3.10.00.04.70.61.70.6STOKStoke Therapeutics3.0628 of 5 stars3.60.00.04.81.51.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARCTArcturus Therapeutics 3.13Buy$59.20549.84% UpsideHRTXHeron Therapeutics 3.00Buy$5.67169.84% UpsideRVNCRevance Therapeutics 2.11Hold$8.39129.75% UpsideSTOKStoke Therapeutics 3.13Buy$24.67315.26% UpsideCurrent Analyst Ratings BreakdownLatest RVNC, STOK, ARCT, and HRTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/19/2025STOKStoke TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$47.00 ➝ $47.003/19/2025STOKStoke TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$24.00 ➝ $24.003/18/2025STOKStoke TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.00 ➝ $22.003/10/2025ARCTArcturus TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$48.003/10/2025ARCTArcturus TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$74.00 ➝ $68.003/7/2025ARCTArcturus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$63.00 ➝ $60.003/7/2025ARCTArcturus TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight3/7/2025ARCTArcturus TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$58.00 ➝ $50.002/28/2025HRTXHeron TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.002/19/2025STOKStoke TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$24.00 ➝ $24.002/18/2025STOKStoke TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$35.00 ➝ $47.00(Data available from 4/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARCTArcturus Therapeutics$138.39M1.79N/AN/A$10.42 per share0.87HRTXHeron Therapeutics$144.29M2.22N/AN/A($0.23) per share-9.13RVNCRevance Therapeutics$234.04M1.63N/AN/A($1.73) per share-2.11STOKStoke Therapeutics$36.56M8.79N/AN/A$3.57 per share1.66Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARCTArcturus Therapeutics-$29.73M-$3.01N/AN/AN/A-36.39%-22.39%-14.81%5/6/2025 (Estimated)HRTXHeron Therapeutics-$110.56M-$0.09N/AN/AN/A-20.31%N/A-12.72%5/6/2025 (Estimated)RVNCRevance Therapeutics-$323.99M-$1.93N/AN/AN/A-74.67%N/A-37.22%5/7/2025 (Estimated)STOKStoke Therapeutics-$104.70M-$1.68N/AN/AN/A-629.90%-54.45%-40.77%5/5/2025 (Estimated)Latest RVNC, STOK, ARCT, and HRTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/5/2025N/ASTOKStoke Therapeutics-$0.42N/AN/AN/A$27.37 millionN/A3/24/2025Q4 2024STOKStoke Therapeutics-$0.56-$0.18+$0.38-$0.18$4.20 million$22.61 million3/6/2025Q4 2024ARCTArcturus Therapeutics-$0.33-$1.11-$0.78-$1.11$44.64 million$22.77 million2/27/2025Q4 2024HRTXHeron Therapeutics-$0.03$0.02+$0.05$0.02$37.37 million$40.78 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARCTArcturus Therapeutics$0.717.85%N/AN/A N/AHRTXHeron TherapeuticsN/AN/AN/AN/AN/ARVNCRevance TherapeuticsN/AN/AN/AN/AN/ASTOKStoke TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARCTArcturus TherapeuticsN/A4.764.76HRTXHeron TherapeuticsN/A2.281.74RVNCRevance TherapeuticsN/A4.123.05STOKStoke TherapeuticsN/A5.095.09Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARCTArcturus Therapeutics94.54%HRTXHeron Therapeutics80.01%RVNCRevance Therapeutics97.70%STOKStoke TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipARCTArcturus Therapeutics15.30%HRTXHeron Therapeutics5.76%RVNCRevance Therapeutics5.10%STOKStoke Therapeutics11.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARCTArcturus Therapeutics18027.12 million22.94 millionOptionableHRTXHeron Therapeutics300152.33 million143.33 millionOptionableRVNCRevance Therapeutics500104.39 million99.07 millionOptionableSTOKStoke Therapeutics10054.08 million46.98 millionOptionableRVNC, STOK, ARCT, and HRTX HeadlinesRecent News About These CompaniesStoke Therapeutics to Present at the 24th Annual Needham Virtual Healthcare ConferenceApril 1, 2025 | businesswire.comStoke Therapeutics remains significantly undervalued, says CanaccordApril 1, 2025 | markets.businessinsider.comResearch Analysts Set Expectations for STOK FY2025 EarningsMarch 29, 2025 | americanbankingnews.comWhat is Chardan Capital's Forecast for STOK FY2025 Earnings?March 28, 2025 | marketbeat.comCantor Fitzgerald Issues Positive Forecast for STOK EarningsMarch 24, 2025 | marketbeat.comEarnings Beat: Stoke Therapeutics, Inc. (NASDAQ:STOK) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their ForecastsMarch 22, 2025 | finance.yahoo.comWhat is HC Wainwright's Forecast for STOK Q3 Earnings?March 22, 2025 | marketbeat.comLeerink Partnrs Weighs in on STOK Q1 EarningsMarch 22, 2025 | marketbeat.comQ1 EPS Estimate for Stoke Therapeutics Lifted by AnalystMarch 22, 2025 | marketbeat.comStoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Recommendation of "Buy" by BrokeragesMarch 22, 2025 | marketbeat.comInsider Selling: Stoke Therapeutics, Inc. (NASDAQ:STOK) General Counsel Sells 2,266 Shares of StockMarch 21, 2025 | marketbeat.comInsider Selling: Stoke Therapeutics, Inc. (NASDAQ:STOK) Insider Sells 3,884 Shares of StockMarch 21, 2025 | marketbeat.comInsider Selling: Stoke Therapeutics, Inc. (NASDAQ:STOK) Director Sells 10,382 Shares of StockMarch 21, 2025 | marketbeat.comEquities Analysts Offer Predictions for STOK Q1 EarningsMarch 21, 2025 | marketbeat.comStoke Therapeutics, Inc. (NASDAQ:STOK) General Counsel Jonathan Allan Sells 2,266 SharesMarch 21, 2025 | insidertrades.comStoke Therapeutics' (STOK) Buy Rating Reiterated at HC WainwrightMarch 20, 2025 | marketbeat.comStoke Therapeutics' (STOK) "Buy" Rating Reiterated at Chardan CapitalMarch 20, 2025 | marketbeat.comThe Escalator: Stoke Therapeutics, Merck, Sutro Biopharma and moreMarch 19, 2025 | mmm-online.comNeedham & Company LLC Reaffirms "Buy" Rating for Stoke Therapeutics (NASDAQ:STOK)March 19, 2025 | marketbeat.comStoke Therapeutics (NASDAQ:STOK) Posts Quarterly Earnings Results, Beats Expectations By $0.38 EPSMarch 19, 2025 | marketbeat.com2STOK : Forecasting The Future: 7 Analyst Projections For Stoke TherapeuticsMarch 19, 2025 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesBYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?By Jeffrey Neal Johnson | March 21, 2025View BYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a BuyBy Thomas Hughes | March 12, 2025View NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy3 Defense Stocks Set to Benefit From Increased Military SpendingBy Chris Markoch | March 20, 2025View 3 Defense Stocks Set to Benefit From Increased Military SpendingArcher Aviation Stock Climbs as Midnight eVTOL Nears RealityBy Jeffrey Neal Johnson | March 10, 2025View Archer Aviation Stock Climbs as Midnight eVTOL Nears RealityRecession Risk: Is It Going to Happen? Here Are the Key CluesBy Jea Yu | March 26, 2025View Recession Risk: Is It Going to Happen? Here Are the Key CluesRVNC, STOK, ARCT, and HRTX Company DescriptionsArcturus Therapeutics NASDAQ:ARCT$9.11 -0.37 (-3.90%) Closing price 04/4/2025 04:00 PM EasternExtended Trading$9.46 +0.35 (+3.89%) As of 04/4/2025 05:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.Heron Therapeutics NASDAQ:HRTX$2.10 -0.04 (-1.87%) Closing price 04/4/2025 04:00 PM EasternExtended Trading$2.03 -0.07 (-3.33%) As of 04/4/2025 06:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.Revance Therapeutics NASDAQ:RVNC$3.65 0.00 (0.00%) As of 02/6/2025Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX that is in preclinical stage. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; and RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.Stoke Therapeutics NASDAQ:STOK$5.94 -0.36 (-5.71%) Closing price 04/4/2025 04:00 PM EasternExtended Trading$5.94 0.00 (0.00%) As of 04/4/2025 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 03/31 - 04/04 Newsmax’s IPO Whiplash: Meme Stock Hype or Growth Potential? Conagra Stock Could Thrive as Tariffs Hit Other Sectors Archer Aviation’s Africa Deal Could Boost ACHR Stock The Ecosystem Edge: Joby's Competitive Advantage Advance Auto Parts Stock: A Classic Rebound Play in the Making Intel’s Big Bet on 18A: Will Lip-Bu Tan’s Vision Pay Off? Lamb Weston Stock Rises, Earnings Provide Calm Amidst Chaos Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
